We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Jul-2024
Active ingredients
tislelizumab
Proposed indication
For the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Application type
C (new indication)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.